Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.

Krens LL, Baas JM, Guchelaar HJ, Gelderblom H.

Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.

2.

How Human Amygdala and Bed Nucleus of the Stria Terminalis May Drive Distinct Defensive Responses.

Klumpers F, Kroes MCW, Baas JMP, Fernández G.

J Neurosci. 2017 Oct 4;37(40):9645-9656. doi: 10.1523/JNEUROSCI.3830-16.2017. Epub 2017 Sep 11.

3.

A fatal case of metastatic squamous cell carcinoma in a patient with myositis ossificans traumatica.

Vlasveld IN, Scheper H, Stalenhoef J, Baas JM, van Dissel J.

Neth J Med. 2017 Jul;75(6):250-252.

4.

The Effects of β-Adrenergic Blockade on the Degrading Effects of Eye Movements on Negative Autobiographical Memories.

Littel M, Kenemans JL, Baas JMP, Logemann HNA, Rijken N, Remijn M, Hassink RJ, Engelhard IM, van den Hout MA.

Biol Psychiatry. 2017 Oct 15;82(8):587-593. doi: 10.1016/j.biopsych.2017.03.012. Epub 2017 Mar 28.

PMID:
28456330
5.

Enhancing effects of contingency instructions on fear acquisition and extinction in anxiety disorders.

Duits P, Richter J, Baas JMP, Engelhard IM, Limberg-Thiesen A, Heitland I, Hamm AO, Cath DC.

J Abnorm Psychol. 2017 May;126(4):378-391. doi: 10.1037/abn0000266. Epub 2017 Apr 17.

PMID:
28414478
6.

Don't fear 'fear conditioning': Methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear.

Lonsdorf TB, Menz MM, Andreatta M, Fullana MA, Golkar A, Haaker J, Heitland I, Hermann A, Kuhn M, Kruse O, Meir Drexler S, Meulders A, Nees F, Pittig A, Richter J, Römer S, Shiban Y, Schmitz A, Straube B, Vervliet B, Wendt J, Baas JMP, Merz CJ.

Neurosci Biobehav Rev. 2017 Jun;77:247-285. doi: 10.1016/j.neubiorev.2017.02.026. Epub 2017 Mar 3. Review.

7.

Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia.

Duits P, Klein Hofmeijer-Sevink M, Engelhard IM, Baas JMP, Ehrismann WAM, Cath DC.

J Behav Ther Exp Psychiatry. 2016 Sep;52:99-104. doi: 10.1016/j.jbtep.2016.03.014. Epub 2016 Apr 1.

PMID:
27061246
8.

High Current Anxiety Symptoms, But Not a Past Anxiety Disorder Diagnosis, are Associated with Impaired Fear Extinction.

Duits P, Cath DC, Heitland I, Baas JM.

Front Psychol. 2016 Feb 26;7:252. doi: 10.3389/fpsyg.2016.00252. eCollection 2016.

9.

Human fear acquisition deficits in relation to genetic variants of the corticotropin-releasing hormone receptor 1 and the serotonin transporter--revisited.

Heitland I, Groenink L, van Gool JM, Domschke K, Reif A, Baas JM.

Genes Brain Behav. 2016 Feb;15(2):209-20. doi: 10.1111/gbb.12276. Epub 2016 Jan 18.

10.

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.

Baas JM, Krens LL, ten Tije AJ, Erdkamp F, van Wezel T, Morreau H, Gelderblom H, Guchelaar HJ.

Invest New Drugs. 2015 Dec;33(6):1242-7. doi: 10.1007/s10637-015-0285-8. Epub 2015 Sep 19.

11.

Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors.

Bijlsma EY, Hendriksen H, Baas JM, Millan MJ, Groenink L.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1733-43. doi: 10.1016/j.euroneuro.2015.07.004. Epub 2015 Jul 20.

12.

Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients.

Baas JM, Krens LL, Bos MM, Portielje JE, Batman E, van Wezel T, Morreau H, Guchelaar HJ, Gelderblom H.

Anticancer Drugs. 2015 Sep;26(8):872-7. doi: 10.1097/CAD.0000000000000255.

PMID:
26053280
13.

Updated meta-analysis of classical fear conditioning in the anxiety disorders.

Duits P, Cath DC, Lissek S, Hox JJ, Hamm AO, Engelhard IM, van den Hout MA, Baas JM.

Depress Anxiety. 2015 Apr;32(4):239-53. doi: 10.1002/da.22353. Epub 2015 Feb 20. Review.

PMID:
25703487
14.

The impact of cue learning, trait anxiety and genetic variation in the serotonin 1A receptor on contextual fear.

Baas JM, Heitland I.

Int J Psychophysiol. 2015 Dec;98(3 Pt 2):506-14. doi: 10.1016/j.ijpsycho.2014.10.016. Epub 2014 Nov 6.

PMID:
25448266
15.

Dorsomedial Prefrontal Cortex Mediates the Impact of Serotonin Transporter Linked Polymorphic Region Genotype on Anticipatory Threat Reactions.

Klumpers F, Kroes MC, Heitland I, Everaerd D, Akkermans SE, Oosting RS, van Wingen G, Franke B, Kenemans JL, Fernández G, Baas JM.

Biol Psychiatry. 2015 Oct 15;78(8):582-9. doi: 10.1016/j.biopsych.2014.07.034. Epub 2014 Aug 27.

PMID:
25444169
16.

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.

Krens LL, Simkens LH, Baas JM, Koomen ER, Gelderblom H, Punt CJ, Guchelaar HJ.

PLoS One. 2014 Nov 6;9(11):e112201. doi: 10.1371/journal.pone.0112201. eCollection 2014.

17.

No impact of deep brain stimulation on fear-potentiated startle in obsessive-compulsive disorder.

Baas JM, Klumpers F, Mantione MH, Figee M, Vulink NC, Schuurman PR, Mazaheri A, Denys D.

Front Behav Neurosci. 2014 Sep 9;8:305. doi: 10.3389/fnbeh.2014.00305. eCollection 2014.

18.

Genetic variability in the human cannabinoid receptor 1 is associated with resting state EEG theta power in humans.

Heitland I, Kenemans JL, Böcker KB, Baas JM.

Behav Brain Res. 2014 Nov 1;274:344-8. doi: 10.1016/j.bbr.2014.08.003. Epub 2014 Aug 10.

PMID:
25116250
19.

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1303-6. doi: 10.1007/s00280-014-2462-4. Epub 2014 Apr 6.

20.

Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report.

Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H.

Cancer Chemother Pharmacol. 2014 Feb;73(2):429-33. doi: 10.1007/s00280-013-2353-0. Epub 2013 Nov 21.

PMID:
24258455
21.

Impaired fear inhibition learning predicts the persistence of symptoms of posttraumatic stress disorder (PTSD).

Sijbrandij M, Engelhard IM, Lommen MJ, Leer A, Baas JM.

J Psychiatr Res. 2013 Dec;47(12):1991-7. doi: 10.1016/j.jpsychires.2013.09.008. Epub 2013 Sep 20.

22.

Human fear acquisition deficits in relation to genetic variants of the corticotropin releasing hormone receptor 1 and the serotonin transporter.

Heitland I, Groenink L, Bijlsma EY, Oosting RS, Baas JM.

PLoS One. 2013 May 22;8(5):e63772. doi: 10.1371/journal.pone.0063772. Print 2013.

23.

Auditory event-related potentials (P3a, P3b) and genetic variants within the dopamine and serotonin system in healthy females.

Heitland I, Kenemans JL, Oosting RS, Baas JM, Böcker KB.

Behav Brain Res. 2013 Jul 15;249:55-64. doi: 10.1016/j.bbr.2013.04.013. Epub 2013 Apr 22.

PMID:
23619133
24.

Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1.

Heitland I, Klumpers F, Oosting RS, Evers DJ, Leon Kenemans J, Baas JM.

Transl Psychiatry. 2012 Sep 25;2:e162. doi: 10.1038/tp.2012.90.

25.

Genetic polymorphisms of the dopamine and serotonin systems modulate the neurophysiological response to feedback and risk taking in healthy humans.

Heitland I, Oosting RS, Baas JM, Massar SA, Kenemans JL, Böcker KB.

Cogn Affect Behav Neurosci. 2012 Dec;12(4):678-91. doi: 10.3758/s13415-012-0108-8.

26.

Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans.

Klumpers F, Denys D, Kenemans JL, Grillon C, van der Aart J, Baas JM.

J Psychopharmacol. 2012 Apr;26(4):471-8. doi: 10.1177/0269881111431624. Epub 2012 Feb 20.

27.

Individual differences in predicting aversive events and modulating contextual anxiety in a context and cue conditioning paradigm.

Baas JM.

Biol Psychol. 2013 Jan;92(1):17-25. doi: 10.1016/j.biopsycho.2012.02.001. Epub 2012 Feb 10.

PMID:
22342768
28.

Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.

Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong FA, Lavrijsen AP, Gelderblom H.

Cancer Treat Rev. 2012 Aug;38(5):505-14. doi: 10.1016/j.ctrv.2011.09.004. Epub 2011 Nov 17. Review.

PMID:
22100458
29.

Genetic variation in serotonin transporter function affects human fear expression indexed by fear-potentiated startle.

Klumpers F, Heitland I, Oosting RS, Kenemans JL, Baas JM.

Biol Psychol. 2012 Feb;89(2):277-82. doi: 10.1016/j.biopsycho.2011.10.018. Epub 2011 Nov 7.

PMID:
22061270
30.

Attentional bias in high- and low-anxious individuals: evidence for threat-induced effects on engagement and disengagement.

Massar SA, Mol NM, Kenemans JL, Baas JM.

Cogn Emot. 2011 Aug;25(5):805-17. doi: 10.1080/02699931.2010.515065. Epub 2011 May 24.

PMID:
21824022
31.

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H.

Oncologist. 2011;16(9):1239-49. doi: 10.1634/theoncologist.2011-0024. Epub 2011 Jul 8. Review.

32.

Prefrontal mechanisms of fear reduction after threat offset.

Klumpers F, Raemaekers MA, Ruigrok AN, Hermans EJ, Kenemans JL, Baas JM.

Biol Psychiatry. 2010 Dec 1;68(11):1031-8. doi: 10.1016/j.biopsych.2010.09.006.

PMID:
21075229
33.

Therapeutic modulation of k-ras signaling in colorectal cancer.

Krens LL, Baas JM, Gelderblom H, Guchelaar HJ.

Drug Discov Today. 2010 Jul;15(13-14):502-16. doi: 10.1016/j.drudis.2010.05.012. Epub 2010 Jun 2. Review.

PMID:
20594936
34.

Atypical Cushing's syndrome caused by ectopic ACTH secretion of an oesophageal adenocarcinoma.

Baas JM, Kapiteijn E, Pereira AM, Nortier JW.

Neth J Med. 2010 Jun;68(6):265-7.

35.

Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.

Baas JM, Mol N, Kenemans JL, Prinssen EP, Niklson I, Xia-Chen C, Broeyer F, van Gerven J.

Psychopharmacology (Berl). 2009 Jul;205(1):73-84. doi: 10.1007/s00213-009-1516-5. Epub 2009 May 5. Erratum in: Psychopharmacology (Berl). 2010 Jun;210(3):451.

36.

Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans.

Klumpers F, van Gerven JM, Prinssen EP, Niklson I, Roesch F, Riedel WJ, Kenemans JL, Baas JM.

J Psychopharmacol. 2010 May;24(5):657-66. doi: 10.1177/0269881109103115. Epub 2009 Mar 27.

PMID:
19329545
37.

A decomposition of electrocortical activity as a function of spatial frequency: a weighted multidimensional scaling analysis.

Melis C, Baas JM, Kenemans JL, Mangun GR.

Brain Res. 2008 Jun 12;1214:116-26. doi: 10.1016/j.brainres.2008.01.098.

PMID:
18471806
38.

Failure to condition to a cue is associated with sustained contextual fear.

Baas JM, van Ooijen L, Goudriaan A, Kenemans JL.

Acta Psychol (Amst). 2008 Mar;127(3):581-92. Epub 2007 Nov 28.

PMID:
18048004
39.

Exogenous testosterone attenuates the integrated central stress response in healthy young women.

Hermans EJ, Putman P, Baas JM, Gecks NM, Kenemans JL, van Honk J.

Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):1052-61. Epub 2007 Sep 27.

PMID:
17904297
40.

Emotion regulation and potentiated startle across affective picture and threat-of-shock paradigms.

Lissek S, Orme K, McDowell DJ, Johnson LL, Luckenbaugh DA, Baas JM, Cornwell BR, Grillon C.

Biol Psychol. 2007 Sep;76(1-2):124-33. Epub 2007 Jul 13.

41.

Startle potentiation in rapidly alternating conditions of high and low predictability of threat.

Mol N, Baas JM, Grillon C, van Ooijen L, Kenemans JL.

Biol Psychol. 2007 Sep;76(1-2):43-51. Epub 2007 Jun 7.

PMID:
17644240
42.

Neural responses to auditory stimulus deviance under threat of electric shock revealed by spatially-filtered magnetoencephalography.

Cornwell BR, Baas JM, Johnson L, Holroyd T, Carver FW, Lissek S, Grillon C.

Neuroimage. 2007 Aug 1;37(1):282-9. Epub 2007 May 18.

43.

Context conditioning and behavioral avoidance in a virtual reality environment: effect of predictability.

Grillon C, Baas JM, Cornwell B, Johnson L.

Biol Psychiatry. 2006 Oct 1;60(7):752-9. Epub 2006 Sep 1.

PMID:
16950216
44.

The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle.

Grillon C, Baas JM, Pine DS, Lissek S, Lawley M, Ellis V, Levine J.

Biol Psychiatry. 2006 Oct 1;60(7):760-6. Epub 2006 Apr 21.

PMID:
16631127
45.

A single administration of testosterone reduces fear-potentiated startle in humans.

Hermans EJ, Putman P, Baas JM, Koppeschaar HP, van Honk J.

Biol Psychiatry. 2006 May 1;59(9):872-4. Epub 2006 Feb 3.

PMID:
16458259
46.

Brainstem correlates of defensive states in humans.

Baas JM, Milstein J, Donlevy M, Grillon C.

Biol Psychiatry. 2006 Apr 1;59(7):588-93. Epub 2006 Jan 4.

PMID:
16388780
47.

Sensation seeking and the aversive motivational system.

Lissek S, Baas JM, Pine DS, Orme K, Dvir S, Rosenberger E, Grillon C.

Emotion. 2005 Dec;5(4):396-407.

PMID:
16366744
48.

Cortisol and DHEA-S are associated with startle potentiation during aversive conditioning in humans.

Grillon C, Pine DS, Baas JM, Lawley M, Ellis V, Charney DS.

Psychopharmacology (Berl). 2006 Jun;186(3):434-41. Epub 2005 Jul 29.

49.

Airpuff startle probes: an efficacious and less aversive alternative to white-noise.

Lissek S, Baas JM, Pine DS, Orme K, Dvir S, Nugent M, Rosenberger E, Rawson E, Grillon C.

Biol Psychol. 2005 Mar;68(3):283-97.

PMID:
15620795
50.

Differences in startle modulation during instructed threat and selective attention.

Böcker KB, Baas JM, Kenemans JL, Verbaten MN.

Biol Psychol. 2004 Nov;67(3):343-58.

PMID:
15294391

Supplemental Content

Support Center